Sumitomo Mitsui Financial Group Begins Coverage on Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Sumitomo Mitsui Financial Group started coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) in a research report released on Wednesday, Briefing.com reports. The brokerage issued an outperform rating and a $80.00 price target on the biotechnology company’s stock. A number of other equities analysts have also recently commented on the stock. StockNews.com started […]

Related Keywords

China ,Arizona ,United States ,Robertw Baird ,Adeoyey Olukotun ,Piper Sandler ,Sumitomo Mitsui Financial Group ,Hennion Walsh Asset Management Inc ,Analyst Recommendations For Arrowhead Pharmaceuticals ,Arrowhead Pharmaceuticals Trading ,Stratos Wealth Partners ,China Universal Asset Management Co ,Arrowhead Pharmaceuticals Company Profile ,Institutional Investors Weigh In On Arrowhead Pharmaceuticals ,Arrowhead Pharmaceuticals ,News Ratings For Arrowhead Pharmaceuticals Daily ,Arrowhead Pharmaceuticals Inc ,Get Rating ,Moderate Buy ,Director Adeoye ,Director Douglas ,Michigan Retirement System ,Universal Asset Management ,Wealth Partners ,State Retirement System ,Walsh Asset Management ,Arrowhead Pharmaceuticals Daily ,Nasdaq Arwr ,Arwr ,Medical ,Initiated Coverage ,Sumitomo Mitsui Financial Group Inc ,